1 Confavreux C, Vukusic S. Natural history of multiple sclerosis. Brain. 2006;129(Pt 3):606–16.
2 Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014;83(3):278–86.
3 Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8(11):647–56.
4 Saidha S, Al-Louzi O, Ratchford JN Bhargava P, Oh J, Newsome SD, et al. Optical coherence tomography reflects brain atrophy in multiple sclerosis: a four-year study. Ann Neurol. 2015;78(5):801–13.
5 Beer S, Khan F, Kesselring J. Rehabilitation interventions in multiple sclerosis: an overview. J Neurol. 2012;259(9):1994–2008.
6 Kobelt G, Berg J, Lindgren P, Elias WG, Flachenecker P, Freidel M, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ. 2006;7(Suppl 2):S34–44.
7 Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;30:299–302.
8 Plantone D, De Angelis F, Doshi A, Chataway J. Secondary Multiple Sclerosis: Definition and Measurement. CNS Drugs. 2016;30:517–26.
9 Marrie RA, Elliot L, Marriott J, Cossoy M, Tennakoon A, Yu N, et al. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology. 2015;84(4):350–58.
10 Feinstein A, Freeman J, Lo A. Treatment of progressive multiple sclerosis: Lancet Neurol. 2015;14:194–207.
11 Khan F, Amatya B: Rehabilitation in Multiple Sclerosis: a systematic review of systematic reviews. Arch Phys Med Rehab. 2017;98:353–67.
12 Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high-dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. JNNP. 1987;50:511–16.
13 Craig J, Young CA, Ennis M, Baker G, Boggild M. A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. J Neurol Neurosurg Psychiatry. 2003;74(9):1225–30.
14 Goodman AD, Brown TE, Krupp LB, Schapiro RT, Schwid SR, Cohen R, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009; 373(9665):732–8.
15 Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur Neurol. 2011;18:1122–31.
16 Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22(13):1719–22.
17 Tomassini V, Matthews PM, Thompson AJ, Fuglo D, Geurts JJ, Johansen-Berg H, et al. Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol. 2012;8(11):635–46.
18 Bansi J, Bloch W, Gamper U, Kesselring J. Training in MS: influence of two different endurance training protocol (aquatic versus overland) on cytokine and neurotrophin concentrations during three week randomized controlled trial. Mult Scler. 2013;19(5):613–21.
19 Briken S, Rosenkranz SC, Keminer O, Patra S, Ketels G, Heesen C, et al. Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis. J Neuroimmunol. 2016;299:53–8.
20 Freeman JA, Langdon DW, Hobart JC, Thompson AJ. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol. 1997;42:236–44.
21 Solari A, Fillipini G, Gasco P, Colla L, Salmaggi A, La Mantia L, et al. Physical therapy has a positive effect on disability in multiple sclerosis patients. Neurology. 1999;52(1):57–62.